ImmunoGen, Inc. (IMGN)
(Delayed Data from NSDQ)
$2.88 USD
+0.38 (15.20%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.93 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
IMGN 2.88 +0.38(15.20%)
Will IMGN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for IMGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IMGN
Corvus' (CRVS) Lymphoma Drug Gets Orphan Status, Stock Up
Humacyte (HUMA) Up on HAV BLA Priority Tag for Vascular Trauma
IMGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ionis' (IONS) Eplontersen Gets Fast Track Tag for New Indication
Foghorn (FHTX) Jumps 55% as Lilly Takes Up FHD-909 Development
Is ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year?